Fatal ventricular arrhythmias after osimertinib treatment for lung adenocarcinoma: a case report.
作者信息
Guo Gui-Gao, Luo Xin, Zhu Ke, Li Ling-Ling, Ou Yang-Fan
机构信息
Cardiovascular Department, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China.
出版信息
J Geriatr Cardiol. 2023 Mar 28;20(3):242-246. doi: 10.26599/1671-5411.2023.03.009.
Abstract
摘要
相似文献
1
Fatal ventricular arrhythmias after osimertinib treatment for lung adenocarcinoma: a case report.
J Geriatr Cardiol. 2023 Mar 28;20(3):242-246. doi: 10.26599/1671-5411.2023.03.009.
2
Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report.
Medicine (Baltimore). 2020 Oct 16;99(42):e22628. doi: 10.1097/MD.0000000000022628.
3
Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
Ann Transl Med. 2021 Jun;9(11):950. doi: 10.21037/atm-21-2823.
4
Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790 M point mutation: a case report.
BMC Cancer. 2019 Feb 28;19(1):186. doi: 10.1186/s12885-019-5399-5.
5
Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report.
Respir Med Case Rep. 2016 Nov 15;20:25-27. doi: 10.1016/j.rmcr.2016.11.009. eCollection 2017.
6
Overdrive pacing in the acute management of osimertinib-induced ventricular arrhythmias: A case report and literature review.
Front Cardiovasc Med. 2022 Sep 29;9:934214. doi: 10.3389/fcvm.2022.934214. eCollection 2022.
7
Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations.
Intern Med. 2018 Dec 15;57(24):3643-3645. doi: 10.2169/internalmedicine.0923-18. Epub 2018 Aug 24.
8
[Pulmonary manifestations induced by osimertinib].
Rev Mal Respir. 2022 Jan;39(1):62-66. doi: 10.1016/j.rmr.2021.12.002. Epub 2021 Dec 27.
9
Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report.
Mol Clin Oncol. 2017 Apr;6(4):525-528. doi: 10.3892/mco.2017.1181. Epub 2017 Mar 3.
10
Successful osimertinib retreatment after extremely early onset severe pneumonitis in first-line treatment of lung adenocarcinoma.
Thorac Cancer. 2020 Sep;11(9):2713-2716. doi: 10.1111/1759-7714.13565. Epub 2020 Jul 15.
引用本文的文献
1
Ethyl acetate extract of : a specific and potent inhibitor against the drug-resistant EGFR_T790M mutant in NSCLC.
Front Pharmacol. 2025 Apr 29;16:1570108. doi: 10.3389/fphar.2025.1570108. eCollection 2025.
2
Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond.
Front Pharmacol. 2024 Aug 15;15:1404692. doi: 10.3389/fphar.2024.1404692. eCollection 2024.
3
Cardiac Arrhythmias in Patients Treated for Lung Cancer: A Review.
Cancers (Basel). 2023 Dec 6;15(24):5723. doi: 10.3390/cancers15245723.
4
Osimertinib induced adverse cardiac events: a case report.
J Geriatr Cardiol. 2023 Sep 28;20(9):702-706. doi: 10.26599/1671-5411.2023.09.006.
本文引用的文献
1
Overdrive pacing in the acute management of osimertinib-induced ventricular arrhythmias: A case report and literature review.
Front Cardiovasc Med. 2022 Sep 29;9:934214. doi: 10.3389/fcvm.2022.934214. eCollection 2022.
2
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
Oncologist. 2022 Nov 3;27(11):903-e834. doi: 10.1093/oncolo/oyac193.
3
Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.
Front Mol Biosci. 2022 Feb 28;9:847835. doi: 10.3389/fmolb.2022.847835. eCollection 2022.
4
Drug-induced QT Prolongation Atlas (DIQTA) for enhancing cardiotoxicity management.
Drug Discov Today. 2022 Mar;27(3):831-837. doi: 10.1016/j.drudis.2021.10.009. Epub 2021 Oct 27.
5
Cardiac Adverse Events in -Mutated Non-Small Cell Lung Cancer Treated With Osimertinib.
JACC CardioOncol. 2020 Mar 17;2(1):1-10. doi: 10.1016/j.jaccao.2020.02.003. eCollection 2020 Mar.
6
Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS).
JACC CardioOncol. 2019 Dec 17;1(2):172-178. doi: 10.1016/j.jaccao.2019.10.006. eCollection 2019 Dec.
7
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
Breast Cancer Res Treat. 2021 Jul;188(1):21-36. doi: 10.1007/s10549-021-06280-x. Epub 2021 Jun 11.
8
Successful Management of Refractory Torsades De Pointes Due to Drug-Induced Long QT Syndrome Guided by Point-of-Care Monitoring of Ionized Magnesium.
Cureus. 2021 Mar 17;13(3):e13939. doi: 10.7759/cureus.13939.
9
Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma.
Int Cancer Conf J. 2020 Oct 15;10(1):68-71. doi: 10.1007/s13691-020-00450-2. eCollection 2021 Jan.
10
Cardiac Safety of Osimertinib: A Review of Data.
J Clin Oncol. 2021 Feb 1;39(4):328-337. doi: 10.1200/JCO.20.01171. Epub 2020 Dec 23.
Zotero 插件